Authors on the Web
Brightsurf Science News, June 19, 2012
...developing another, and understanding the underlying immune process can reverse a patients... by Donna Jackson Nakazawa (Author), Dr. Douglas Kerr (Foreword) From the foreword by Dr. Douglas Kerr, Director, Johns Hopkins Transverse Myelitis Center "The...
Brightsurf Science News, June 12, 2012
...and includes updated discussion of B and T cell memory, T cell... by Donna Jackson Nakazawa (Author), Dr. Douglas Kerr (Foreword) From the foreword by Dr. Douglas Kerr, Director, Johns Hopkins Transverse Myelitis Center "The Autoimmune Epidemic by Donna...
Brightsurf Science News, June 5, 2012
...links. Covers the most up-to-date immunology information including regulatory T cells, and... by Donna Jackson Nakazawa (Author), Dr. Douglas Kerr (Foreword) From the foreword by Dr. Douglas Kerr, Director, Johns Hopkins Transverse Myelitis Center "The...
Brightsurf Science News, June 4, 2012
...links. Covers the most up-to-date immunology information including regulatory T cells, and... by Donna Jackson Nakazawa (Author), Dr. Douglas Kerr (Foreword) From the foreword by Dr. Douglas Kerr, Director, Johns Hopkins Transverse Myelitis Center "The...
Express Pharma, January 19, 2013
...were not what we expected, we hope these data will provide a foundation for future ALS research,” said Douglas Kerr, Director, Neurodegeneration Clinical Research at Biogen Idec. EP News Bureau - Mumbai...
Minnesota Public Radio, January 15, 2013
...in one of these places that I monitor and you know, Dexpramipexole is a wash out." Dr. Douglas Kerr, Biogen's lead medical director for the study and an ALS neurologist, called the trial a "very comprehensive, very large study which was designed to...
Minnesota Public Radio, January 15, 2013
...in one of these places that I monitor and you know, Dexpramipexole is a wash out." Dr. Douglas Kerr, Biogen's lead medical director for the study and an ALS neurologist, called the trial a "very comprehensive, very large study which was designed to...
Minnesota Public Radio, January 15, 2013
...in one of these places that I monitor and you know, Dexpramipexole is a wash out." Dr. Douglas Kerr, Biogen's lead medical director for the study and an ALS neurologist, called the trial a "very comprehensive, very large study which was designed to...
Minnesota Public Radio, January 15, 2013
...in one of these places that I monitor and you know, Dexpramipexole is a wash out." Dr. Douglas Kerr, Biogen's lead medical director for the study and an ALS neurologist, called the trial a "very comprehensive, very large study which was designed to...
CNBC, January 8, 2013
...has treated people with ALS, I hoped with all my heart for a different outcome," said Dr. Douglas Kerr, the company's director of neurodegeneration clinical research Vtsock LLC | Although the developments were heart-breaking for the medical community...
Sentinel Tribune, January 8, 2013
...the 2013 calendar year, and review the current zoning regulations, and discuss any potential changes for the future. Douglas Kerr, Secretary Liberty Township Zoning Commission Jan. 8, '13...

